Wehrwissenschaftliches Institut für Schutztechnologien – ABC-Schutz (Bundeswehr Research Institute for Protective Technologies and CBRN Protection)

2. Emplacement de l’installation (indiquer l’adresse et les coordonnées géographiques)
Humboldtstrasse 100, D-29633 Munster/Oertze, Germany

53°00` N, 10°08` E

3. Superficie des secteurs de laboratoire, par niveau de confinement
BL 3 , 6.00 m2
containment (vehicle bound)
BL 3 , 360.00 m2
stationary laboratories
BL 2 , 520.00 m2
stationary laboratories
Superficie totale des laboratoires (m(2))

4. Organigramme de chaque installation

(viii) Décrire brièvement la politique adoptée en matière de publication dans l’installation.

Results will be published in reports to the Federal Office of Equipment, IT and In-Service Support. They will also be presented in public scientific journals and in national and international scientific meetings and symposiums.

(ix) Fournir une liste des documents et rapports accessibles au public qui portent sur les travaux publiés au cours des douze mois écoulés (indiquer les auteurs, les titres et les références complètes).
  • 1.    Schirmer S, “Herausforderung einer B-Probennahme im Einsatz”, Europäische Sicherheit und Technik, Mittler Report Verlag, 12/2021
  • 2.    Yeh KB, Tabynov K, Parekh FK, Maltseva E, Skiba Y, Shapiyeva Z, Sansyzbai A, Frey S, Essbauer S, Hewson R, Richards AL, Hay J. Building Scientific Capability and Reducing Biological Threats: The Effect of Three Cooperative Bio-Research Programs in Kazakhstan. Front Public Health. 2021 Oct 12;9:683192. doi: 10.3389/fpubh.2021.683192. PMID: 34712634; PMCID: PMC8545806.
  • 3.    Peintner L, Wagner E, Shin A, Tukhanova N, Turebekov N, Abdiyeva K, Spaiser O, Serebrenniko-va Y, Tintrup E, Dmitrovskiy A, Zhalmagambetova A, Frey S, Essbauer SS. Eight Years of Collabo-ration on Biosafety and Biosecurity Issues Between Kazakhstan and Germany as Part of the German Biosecurity Programme and the G7 Global Partnership Against the Spread of Weapons and Materials of Mass Destruction. Front Public Health. 2021 Aug 9;9:649393. doi: 10.3389/fpubh.2021.649393. PMID: 34434910; PMCID: PMC8381731.
  • 4.    Zhigailov AV, Neupokoyeva AS, Maltseva ER, Perfilyeva YV, Bissenbay AO, Turebekov NA, Frey S, Essbauer S, Abdiyeva KS, Ostapchuk YO, Berdygulova ZA, Aimbetov RS, Naizabayeva DA, Dmitrovskiy AM, Skiba YA, Mamadaliyev SM. The prevalence of Borrelia in Ixodes persulcatus in southeastern Kazakhstan. Ticks Tick Borne Dis. 2021 Jul;12(4):101716. doi: 10.1016/j.ttbdis.2021.101716. Epub 2021 Mar 23. PMID: 33812343.
  • 5.    Borde JP, Kaier K, Hehn P, Matzarakis A, Frey S, Bestehorn M, Dobler G, Chitimia-Dobler L. The complex interplay of climate, TBEV vector dynamics and TBEV infection rates in ticks-Monitoring a natural TBEV focus in Germany, 2009-2018. PLoS One. 2021 Jan 7;16(1):e0244668. doi: 10.1371/journal.pone.0244668. PMID: 33411799; PMCID: PMC7790265.
  • 6.    Wieland J, Frey S, Rupp U, Essbauer S, Groß R, Münch J, Walther P. Zika virus replication in glio-blastoma cells: electron microscopic tomography shows 3D arrangement of endoplasmic reticu-lum, replication organelles, and viral ribonucleoproteins. Histochem Cell Biol. 2021 Dec;156(6):527-538. doi: 10.1007/s00418-021-02028-2. Epub 2021 Sep 12. PMID: 34514517; PMCID: PMC8435300.
  • 7.    Turebekov N, Abdiyeva K, Yegemberdiyeva R, Kuznetsov A, Dmitrovskiy A, Yeraliyeva L, Shapiyeva Z, Batyrbayeva D, Tukhanova N, Shin A, Musralina L, Hoelscher M, Froeschl G, Dobler G, Freimueller K, Wagner E, Frey S, Essbauer S. Occurrence of Anti-Rickettsia spp. Antibodies in Hospitalized Patients with Undifferentiated Febrile Illness in the Southern Region of Kazakh-stan. Am J Trop Med Hyg. 2021 Apr 26;104(6):2000-2008. doi: 10.4269/ajtmh.20-0388. PMID: 33901004; PMCID: PMC8176513.
Pièces jointes
5. Décrire succinctement les travaux sur la défense biologique réalisés dans l’installation, y compris le(s) type(s) de micro-organismes(9) et/ou toxines étudiés, et résumer les études en plein air sur les aérosols biologiques.

For these purposes, microbiological safety laboratories of biosafety levels BSL 1- 3 and biosafety S 1 laboratories for genetically engineered agents are operated, which allow development and research in all areas of B-protection and the investigation of suspect samples in case of CBRN scenarios. The mission is to close Bundeswehr capability gaps in B-defense. Development and optimization of the rapid identification/detection of biowarfare agents, development of the elemental basics for the generation and verification of protection factors and both outline and establishment of new and pioneering approaches in decontamination are the primary focus of the biological laboratories and B-detection.

a. Development of early-warning systems permitting non-specific identification of toxins, bacteria and viruses.

b. Optimization of the properties of the available, previously generated detection molecules in their specificity, affinity and avidity for use in the immunological detection and identification systems, which inevitably must be suitable also for field-use. Using new technologies (e.g. development and identification of recombinant antibodies), the repertoire of antibodies and detection molecules for biological agents is constantly expanded.

c. Optimization and automatisation of immunological and molecular genetical identification methods.

d. Development, testing and evaluation of equipment and procedures for sampling and rapid and accurate identification of toxins and pathogenic agents in samples from air, water, soil, vegetation (sensor-equipment, collectors, detection kits, automatisation).

e. Sample concentration and preparation incl. inactivation for identification in different matrices.

f. Efficient sample processing and risk mitigation method for both ensuring safe handling and preparation of the mixed CBRN samples for the following identification analysis of the CBRN agents. Aim is to develop a set of validated procedures for the separation and preparation of a potential mixture of CBRN agents into distinct C, B, RN aliquots for simultaneous, parallel and/or successive identification analyses, independent of sample matrix, without an impact on each CBRN compound and reducing the turn-around-time for analysis.

g. Stability-tests for B-agents in different matrices.

h. Risk assessment Improvised Explosive Devices (IED) plus B-agents.

i. Development, testing and evaluation of equipment and procedures for the decontamination/disinfection/inactivation of pathogenic agents and toxins from different surfaces and materials.

j. B-Agents and toxin laboratory analysis of suspect samples.

k. Toxin preparation and analytics.

l. Biotechnological studies on simulant substances.

m. Participation in round-robin exercises.

The current programme covers non-human/non-animal pathogen biosafety level 1 and pathogenic biosafety level 2 and 3 organisms as well as low-molecular weight and protein toxins. Outdoor studies were performed for biological aerosols detection and water-purification tests using biowarfare agent simulants.


(9) Notamment les virus et prions.